| Title | Can recreational doses of THC produce significant dopamine release in the human striatum? | | Author(s) | Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM | | Institution | Psychiatry Group, MRC Clinical Science Centre, Imperial College, Hammersmith Hospital, London , UK. | | Source | Neuroimage 2009 Jun 16. | | Abstract | Background Cannabis use in early adolescence may be a risk factor for development of schizophrenia. In animals, Delta9-tetrahydrocannabinol (THC) increases the rate of dopamine neuronal firing and release in the striatum. Thus cannabis use may increase dopamine release in the human striatum leading to vulnerability to psychosis Aims To investigate whether THC, the main psychoactive component of cannabis, can produce dopamine release in the human striatum. Methods 13 healthy volunteers, with previous cannabis experience, underwent two [11C]-raclopride positron emission tomography (PET) scans to indirectly measure striatal dopamine levels following either 10mg THC or placebo. Results Although THC markedly increased psychosis-like symptoms on the Psychotomimetic States Inventory (PSI), there was no significant effect of THC on [11C]-raclopride binding Conclusion In the largest study of its kind so far, we have shown that recreational cannabis users do not release significant amounts of dopamine from an oral THC dose equivalent to a standard cannabis cigarette. This result challenges current models of striatal dopamine release as the mechanism mediating cannabis as risk factor for schizophrenia. Declaration of Interest None. Funding detailed in Acknowledgments. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19539765 |
|
